Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00074048 · ClinicalTrials.gov registry record · Phase 2
BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia
A Phase 2 study of Leukemia, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT00074048 is a Phase 2 study of Leukemia that has completed, run by MedImmune. The registered enrollment target is 36 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00074048, a Phase 2 study of Leukemia, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: The BL22 immunotoxin can locate tumor cells and kill them without harming normal cells. This may be an effective treatment for hairy cell leukemia that has not responded to treatment with cladribine. PURPOSE: This phase II trial is studying BL22 immunotoxin to see how well it works in treating patients previously treated with cladribine for hairy cell leukemia.
Conditions Studied
Interventions
- DRUG BL22
Study Locations (1)
Maryland
- Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2003-10 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00074048
The ClinicalTrials.gov registry entry for NCT00074048 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (93% lower). The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which BL22 is the first listed.
NCT00074048 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00074048 about?
NCT00074048 is a clinical study titled "BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia". RATIONALE: The BL22 immunotoxin can locate tumor cells and kill them without harming normal cells. This may be an effective treatment for hairy cell leukemia that has not responded to treatment with cladribine. PURPOSE: This phase II trial is studying BL22 immunotoxin to see how well it works in tr...
What is the current status of trial NCT00074048?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2003-10. Estimated completion is 2008-07.
What conditions does trial NCT00074048 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00074048?
The interventions under investigation include: BL22 (DRUG).
Who is sponsoring clinical trial NCT00074048?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00074048 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
RECRUITING · Phase 2
-
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RECRUITING · Phase 2
-
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 2
-
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.